A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.

doi:10.1007/s00535-013-0925-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.

Journal of gastroenterology - 1 Dec 2014

Nagahara Akihito, Suzuki Tsuyoshi, Nagata Naoyoshi, Sugai Nozomu, Takeuchi Yoshiaki, Sakurai Kouichi, Miyamoto Masaki, Inoue Kazuhiko, Akiyama Junichi, Mabe Katsuhiro, Konuma Ichiro, Kamada Tomoari, Haruma Ken

Abstract excerpt

BACKGROUND: Proton pump inhibitors (PPIs) are affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. This study compared the effect of two PPIs on early symptom relief in Japanese patients with reflux esophagitis, classified by the CYP2C19 phenotype. METHODS: Patients with reflux esophagitis were randomised to treatment with omeprazole 20 mg or rabeprazole 10 mg once daily. The CYP2C19 phenotype [homozygous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Japan

Share to Omeprazole

Share to Phenotype

Share to Polymorphism, Genetic

Share to Proton Pump Inhibitors

Share to Rabeprazole

Source

Open in PubMed Open full text

Identifiers

PMID: 24366288
DOI: 10.1007/s00535-013-0925-8
PMCID: PMC4258614

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.